Presentation is loading. Please wait.

Presentation is loading. Please wait.

Trends in Spending on Selective Beta 2 Agonists in General Practice in England.

Similar presentations


Presentation on theme: "Trends in Spending on Selective Beta 2 Agonists in General Practice in England."— Presentation transcript:

1 Trends in Spending on Selective Beta 2 Agonists in General Practice in England

2 Trends in Usage of Selective Beta 2 Agonists in General Practice in England

3 Trends in Spending on Short-acting Selective Beta 2 Agonists in General Practice in England

4 Trends in Usage of Short-acting Selective Beta 2 Agonists in General Practice in England

5 Trends in Spending on Long-acting Selective Beta 2 Agonists in General Practice in England

6 Trends in Usage of Long-acting Selective Beta 2 Agonists in General Practice in England

7 Trends in Spending on Selective Beta 2 Agonists (by Device) in General Practice in England

8 Trends in Usage of Selective Beta 2 Agonists (by Device) in General Practice in England

9 Trends in Spending on Antimuscarinic Bronchodilators Including Combinations in General Practice in England

10 Trends in Usage of Antimuscarinic Bronchodilators Including Combinations in General Practice in England

11 Trends in Spending on Theophylline and Aminophylline in General Practice in England

12 Trends in Usage of Theophylline and Aminophylline in General Practice in England

13 Trends in Spending on Inhaled Corticosteroids (excluding Combinations) in General Practice in England

14 Trends in Usage of Inhaled Corticosteroids (excluding Combinations) in General Practice in England

15 Trends in Spending on Inhaled Corticosteroids (by Device) in General Practice in England

16 Trends in Usage of Inhaled Corticosteroids (by Device) in General Practice in England

17 Trends in Spending on Seretide® and Symbicort® in General Practice in England

18 Trends in Usage of Seretide® and Symbicort® in General Practice in England

19 Trends in Prescribing of Seretide® Inhaler by Strength in General Practice in England

20 Trends in Spending on Seretide® Inhaler by Strength in General Practice in England

21 Trends in Prescribing of Leukotriene Receptor Antagonists in General Practice in England

22 Trends in Spending on Leukotriene Receptor Antagonists in General Practice in England

23 Trends in Prescribing of Non-Sedating Antihistamines in General Practice in England

24 Trends in Spending on Non-Sedating Antihistamines in General Practice in England

25 Trends in Prescribing of Sedating Antihistamines in General Practice in England

26 Trends in Spending on Sedating Antihistamines in General Practice in England

27 Trends in Prescribing of Adrenaline (BNF 3.4.3 Allergic Emergencies) in General Practice in England

28 Trends in Spending on Adrenaline (BNF 3.4.3 Allergic Emergencies) in General Practice in England

29 Trends in Prescribing of Mucolytics (excluding Dornase Alfa) in General Practice in England

30 Trends in Spending on Mucolytics (excluding Dornase Alfa) in General Practice in England

31 Trends in Prescribing of and Spending on Nicotine Replacement Therapy in General Practice in England

32 Trends in Prescribing of Different Formulations of Nicotine Replacement Therapy in General Practice in England

33 Trends in Spending on Different Formulations of Nicotine Replacement Therapy in General Practice in England

34 Trends in Prescribing of and Spending on Bupropion in General Practice in England

35 Trends in Prescribing of and Spending on Varenicline in General Practice in England

36 Trends in Prescribing of NICE Drugs for Influenza in General Practice in England

37 Trends in Spending on NICE Drugs for Influenza in General Practice in England


Download ppt "Trends in Spending on Selective Beta 2 Agonists in General Practice in England."

Similar presentations


Ads by Google